Plasma proteomic signatures of cellular aging predict human disease

Using more than 7,000 plasma proteins from over 60,000 people, Stanford researchers built blood-based “aging clocks” for more than 40 individual cell types, showing that different cell types in the same body age at wildly different rates — and that these cellular age gaps predict who will get Alzheimer’s, ALS, lung cancer and who will die, up to 15 years in advance.

Aging is not one process. It is dozens of them, running at different speeds inside the same body, and a single tube of blood can now read them out. That is the central claim of a major new study from Tony Wyss-Coray’s group at Stanford, published in Nature Medicine.

The team mapped over 7,000 circulating proteins back to the cell types that secrete them — neurons, astrocytes, skeletal muscle fibres, immune cells, lung cells and more than 40 others — then trained machine-learning “clocks” to estimate the biological age of each cell type from plasma alone. Applied across three large cohorts totalling 60,542 people (the GNPC neurodegeneration consortium, the UK Biobank and Britain’s 1946 birth cohort), the clocks revealed that aging is strikingly asynchronous. Roughly one in four people had one cell type aging abnormally fast while the rest looked normal; a smaller group, 1 to 3 percent, were aging fast across ten or more cell types at once.

The “big idea” is that these cell-specific age gaps are not cosmetic — they forecast disease with surprising specificity. People with extremely aged skeletal muscle cells were over twelve times more likely to later develop ALS. Those with extremely aged astrocytes — the brain’s support cells — carried an Alzheimer’s risk rivalling the notorious APOE4 gene itself, and in APOE4 homozygotes, extreme astrocyte aging tripled lifetime AD risk. Smokers whose lung cells looked old had substantially higher lung-cancer risk than smoking explained on its own.

Crucially, the directionality cuts both ways. Youthful astrocytes cut Alzheimer’s risk by more than 60 percent, and youthful immune and neuronal cells were protective against death overall. The team distilled the whole picture into a single “polycellular aging risk score” that sorted people into mortality tiers across different cohorts and even across two different proteomic platforms — a sign the signal is real and not a quirk of one assay.

The honest caveat: this is an observational study. It shows that aged cells travel with future disease, not that reversing them prevents it. The cohorts skew old and white. But as a framework for seeing aging at cellular resolution from a routine blood draw, it is a genuine step toward personalised, organ-by-organ longevity medicine.

Actionable Insights

This is an observational biomarker study, not an intervention trial — so the “actions” are about risk stratification and the modifiable factors the data implicate, not a pill or protocol the paper tested. With that framing, the take-home effect sizes are large.

Don’t smoke — and know that lung-cell aging compounds the damage. Current smokers had roughly a 10-fold lung-cancer hazard versus never-smokers (HR around 9.69). Smokers who also had extremely aged respiratory cells reached HR 15.33 — a 58 percent higher hazard than smoking alone. Never-smokers sat at the bottom of every curve. [Confidence: High]

Avoid the smoking-plus-obesity combination. People with concurrent smoking and obesity showed broad acceleration of biological age across many cell types, whereas a clean-lifestyle group (never-smoking, BMI under 25, 7+ hours sleep, exercise 5+ days/week, no regular alcohol) showed broadly younger cellular ages. The effect is whole-body, not confined to one organ. [Confidence: Medium]

Cumulative cellular aging is the headline mortality lever. Over 15 years, people with normal cellular aging had about 90 percent survival; those with 20+ extremely aged cell types had about 34 percent survival — a ~56 percentage-point absolute gap, graded across intermediate groups (1–5 cells ~85%, 6–10 ~73%, 11–20 ~52%). Preserving youthful immune and neuronal cells conferred survival equal to or better than normal agers. [Confidence: High for association, Low for modifiability]

The practical message: the established levers (don’t smoke, stay lean, sleep, exercise) track with younger cells, and a future blood test could tell you which of your organs is aging fastest — but the paper does not show that lowering these scores extends your life.

Source:

  • Open Access Paper: Plasma proteomic signatures of cellular aging predict human disease
  • Institution: Stanford University (Wyss-Coray laboratory; Stanford Alzheimer’s Disease Research Center, Knight Initiative for Brain Resilience). Corresponding author: T. Wyss-Coray.
  • Country: United States of America (with UK collaborators — UCL, MRC 1946 NSHD).
  • Journal: Nature Medicine (Springer Nature).
    Impact Evaluation: The impact score of this journal is ~50 (2024 Journal Impact Factor; CiteScore higher still, ~70+, and historically the JIF has ranged into the 80s), evaluated against a typical high-end range of 0–60+ for top general and clinical science journals, therefore this is an Elite impact journal. Nature Medicine sits among the highest-impact venues in all of biomedicine (JCR Q1, top ~20 in Medicine).
1 Like

Novelty — What This Adds That We Didn’t Know Yesterday

Prior aging clocks worked at the organ level (Oh et al. and predecessors) or required tissue biopsy/transcriptomics for cellular resolution. This is the first demonstration that cell-type-specific biological age (40+ cell types) can be reconstructed non-invasively from plasma proteins at population scale, validated across two independent proteomic platforms (SomaScan and Olink) and three cohorts. The specific, novel quantitative findings: skeletal-myocyte aging as a dominant ALS and mortality predictor; astrocyte aging rivalling APOE4 for AD and interacting synergistically with it; respiratory-cell aging adding measurable risk on top of smoking; and a platform-agnostic polycellular score (PARS).

https://www.nature.com/articles/s41591-026-04446-y

chatGPT(5.5paid):

Summary

The paper, “Plasma proteomic signatures of cellular aging predict human disease,” tries to infer cell-type-specific biological aging from blood plasma proteins. The authors map plasma proteins to likely source cell types using Human Protein Atlas single-cell transcriptomic data, then build machine-learning “aging clocks” for more than 40 cell types using plasma proteomics from 60,542 people across three cohorts: GNPC, UK Biobank, and NSHD. They use SomaScan and Olink platforms, which gives some cross-platform validation.

The core method is: identify proteins enriched in particular cell types, train models to predict chronological age from those proteins, then calculate a cell-type “age gap”: predicted cell age minus the expected predicted age for someone of the same chronological age. Positive age gaps are interpreted as accelerated cellular aging; negative age gaps as relative youth. Extreme old or young states are defined as more than two standard deviations from the mean.

The main finding is that aging appears heterogeneous and asynchronous across cell types. In healthy individuals, about 20–25% had accelerated aging in one cell type, while 1–3% had accelerated aging in 10 or more cell types. Some cell types showed late-life acceleration, especially neuronal and glial types, whereas intestinal goblet cells and ciliated cells showed earlier acceleration in some younger individuals.

The disease associations are striking. In neurodegeneration, ALS was most strongly associated with skeletal myocyte aging, and individuals with extreme skeletal myocyte aging had a 12.7-fold higher risk of future ALS compared with youthful skeletal myocytes. Alzheimer’s disease was associated with accelerated aging in several CNS and systemic cell types, especially astrocytes, oligodendrocyte precursor cells, inhibitory neurons, pancreatic endocrine cells, and proximal enterocytes. Extreme astrocyte aging strongly stratified future AD risk and interacted with APOE4 status. APOE4 carriers had older astrocyte signatures but younger macrophage signatures, while APOE2 showed the opposite pattern.

The paper also links cell-type aging signatures to modifiable risk factors. Smoking plus obesity was associated with broadly older cellular profiles, whereas a “healthy lifestyle” profile was associated with younger cellular age estimates. The authors also develop a polycellular aging risk score, which combines cell-type aging information and stratifies mortality risk across cohorts and proteomics platforms.

Novelty

The novelty is not merely another blood-based aging clock. The distinctive claim is that plasma proteomics can be used to infer aging at something approximating cellular resolution, rather than just whole-body, organ-level, or tissue-level biological age.

The most novel elements are:

  1. Cell-type-specific plasma aging clocks
    The paper maps plasma proteins to putative source cell types and then constructs age predictors for individual cell types, including astrocytes, neurons, macrophages, skeletal myocytes, cardiomyocytes, epithelial cells, endocrine cells, and immune lineages.

  2. Disease-specific cellular vulnerability patterns
    The ALS–skeletal myocyte signal and the AD–astrocyte/APOE interaction are particularly interesting because they move beyond “aging is bad” to propose that particular diseases may be predicted by aging signatures in particular cell compartments.

  3. APOE as a cell-type antagonistic aging factor
    APOE4 being associated with older astrocytes but younger macrophages, while APOE2 shows the reverse, is a potentially important biological observation. It fits with an antagonistic pleiotropy framing: immune benefit or altered innate immune state at the cost of CNS vulnerability.

  4. Polycellular aging burden
    The mortality analysis suggests that risk is not just about one “old” tissue, but about the number and identity of aged cell-type signatures. Individuals with many extremely aged cell types had much poorer survival than those with normal or youthful profiles.

Critique

The paper is impressive, but the central inference should be treated cautiously: plasma protein signatures are not the same thing as directly measuring the age of a cell type. The method depends on assigning circulating proteins to likely cell origins using expression enrichment. That is plausible, but many plasma proteins are secreted, processed, cleared, inflammatory, or affected by organ function. A protein enriched in a cell type does not necessarily mean its plasma concentration is a clean readout of that cell type’s intrinsic biological age.

A second issue is that the clocks are trained to predict chronological age, then interpreted as biological aging. That is common in aging-clock work, but it risks circularity. A model can predict age because proteins change with age, but that does not prove the model captures causal aging biology rather than age-associated inflammation, disease burden, renal clearance, medication effects, frailty, or subclinical pathology.

The ALS finding is both exciting and potentially problematic. Extreme skeletal myocyte aging strongly predicts ALS, even years before diagnosis, but ALS has a long prodromal phase. The signal may reflect early occult neuromuscular disease rather than a causal aging process in muscle. In other words, it may be an excellent early disease biomarker without proving that skeletal muscle aging contributes causally to ALS.

The AD findings are similarly important but need careful interpretation. Astrocyte aging may help stratify APOE4 risk, but astrocyte-related plasma proteins could reflect neuroinflammation, blood–brain barrier changes, systemic inflammation, or peripheral correlates of CNS disease. The association with pTau-217 and cognition strengthens biological plausibility, but it still does not prove that “rejuvenating astrocytes” would reduce AD risk.

The cell-type specificity may also be uneven. Some models perform better than others, and some cell types have many more protein features than others. The paper notes that SomaScan and Olink differ in coverage, and Olink required broader lineage-level models in some cases. That means not all cell clocks are equally reliable or equally comparable.

The strongest practical value is probably risk stratification, not mechanistic proof. The work may help identify people at higher risk of ALS, AD, lung cancer, or mortality, and may help prioritize biological pathways. But it should not yet be read as showing that the measured cell types are necessarily the causal origin of the disease process.

Overall assessment

This is a strong and potentially important paper. Its main contribution is a scalable framework for using plasma proteomics to infer heterogeneous cellular aging patterns across the body. The findings on astrocytes/APOE/AD, skeletal myocytes/ALS, respiratory epithelial aging/lung cancer, and polycellular mortality burden are biologically plausible and clinically interesting.

The main weakness is interpretability: the phrase “cellular aging” may overstate what plasma proteins can prove. A more conservative description would be cell-type-enriched plasma proteomic aging signatures. Even with that caveat, the paper is valuable because it generates testable hypotheses and may provide clinically useful biomarkers years before overt disease.